Immunogenicity and Safety of Homologous Booster Doses of CoronaVac COVID-19 Vaccine in Elderly Individuals Aged 60 Years and Older:A Dosing Interval Study—Yunnan Province,China,2021–2022

作     者：Haitao Yang Xing Meng Tingyu Zhuang Cangning Wang Zhongliang Yang Taotao Zhu Mei Li Yan Zheng Qianhui Wu Yaling Hu Hongjie Yu Xiaoqiang Liu Gang Zeng 

作者机构：Yunnan Provincial Center for Disease Control and PreventionKunming CityYunnan ProvinceChina Sinovac Biotech Co.Ltd.Beijing MunicipalityChina School of Public HealthFudan UniversityKey Laboratory of Public Health SafetyMinistry of EducationShanghai MunicipalityChina Yongde County Center for Disease Control and PreventionLincang CityYunnan ProvinceChina Sinovac Life SciencesBeijing MunicipalityChina 

出 版 物：《China CDC weekly》 (中国疾病预防控制中心周报（英文）)

年 卷 期：2023年第5卷第6期

页      面：125-130,I0008-I0012页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Shanghai Roche Pharmaceutical Company and Sinovac Biotech Ltd Sinovac Biotech Ltd Yichang HEC Changjiang Pharmaceutical Company GlaxoSmithKline, GSK Sanofi Pasteur 

主　　题：concentration. doses remarkable 

摘      要：Summary What is already known about this topic?Neutralization levels induced by inactivated vaccines rapidly wane after primary immunization,and a homologous booster can recall specific immune memory,resulting in a remarkable increase in antibody *** optimal interval between primary and booster doses has yet to be determined.